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Introduction
Scarring, both as a component and complication of, wound heal-
ing affects millions of US citizens every year at a cost of more 
than 7 billion dollars (Wilgus, et al. 2003). In addition to esthetic 
concerns, scar formation is also implicated clinically in fibrotic 
diseases that some reports suggest are responsible for up to 45% 
of deaths in the industrial world (Wynn, 2008).  Despite such a 
heavy toll on the healthcare system, current treatment options 
are limited. Further research is needed to understand the under-
lying causes and mechanisms of scar formation so that effective 
treatments and even methods of prevention can be developed. 
Cellular response to tissue damage and the consequent forma-
tion of fibrotic tissue is a complex process that is still not very 
well understood. Current paradigms include the contribution of 
such varied cells as epithelial cells, macrophages, T-cells and, of 
course, fibroblasts. Initial response to tissue wounds involves the 
rapid recruitment of clotting factors and immune inflammatory 
moderators to stem blood loss and reduce potential infection 
by pathogenic microbes. Later, the relatively extended process of 
wound healing begins. Injured epithelial cells undergo a process 
of reprogramming, initiation, and propagation of mesenchymal 
pathways that includes the ubiquitous TGF-β related pathways. 
Macrophages also contribute to the inflammatory response and 
secrete profibrotic cytokines as well as growth factors, including 
TGF-β, that recruit and activate fibroblasts. Fibroblasts accumu-
late and ultimately produce and deposit new extracellular matrix 
and collagen that replaces normal tissue architecture. It is this 
deposition that characterizes scar formation and clinical fibrosis.
Interestingly, the development of scar tissue differs greatly be-
tween adult and embryonic wounds. Contrary to the normal 
fibrotic result in adult wounds, fetal wounds have been shown to 
exhibit scarless healing. Many cellular and molecular differences, 
including differences in key inflammatory mediators and various 
cytokines and growth factors, have been studied and documented 
to attempt to explain this phenomenon. 
In addition to expected scarring as a result of injury, there exist 
two clinical examples of atypical wound healing that result in ab-
normal scar formation. The etiology of hypertrophic scars and 
keloids is not well-understood, and although important differ-
ences between them have been detailed, both clearly involve the 
deposition of excessive amounts of collagen even as compared 
to normal scarring. 
Such anomalous results, from the scarless healing of fetal wounds 
to the excessive scarring of keloid and hypertrophic scars, may 
serve as paradigms for understanding the mechanisms behind the 
wound healing and scarring processes and the ability to prevent 
undesired outcomes.
Methods
Literature searches were chiefly performed using the PubMed 
database. After relevant literature was found, related articles 
were accessed using the Related Citations feature on the PubMed 
website. Additionally, references in these articles were retrieved 
and then served as additional points of reference for further re-
search. Review articles relevant to the research topic were help-
ful in providing references to source material. The Touro College 
Online Library and Google Scholar proved to be valuable for 
finding and accessing the necessary relevant articles. Moreover, 
conversation with plastic surgeons led to additional searches for 
source material on the website of the Plastic and Reconstructive 
Surgery journal.
Discussion
The formation of scar tissue in the process of wound healing is 
both a positive construct that effectively patches breaks in dam-
aged tissue and a negative consequence that can have dire effects. 
Scar tissue production is intended to increase the tensile the 
strength of wounds but never surpasses 70% of the strength of 
the original undamaged tissue (Wilgus, et al. 2003). Scar tissue 
also can impede tissue function, restricting mobility in joints and 
impairing normal growth in the case of external injuries involving 
the skin. The issue is even more problematic in the case of scar 
deposition as a result of internal organ damage. In such cases, 
scars can dramatically reduce function of vital organs as with 
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victims of myocardial infarctions whereby normal heart tissue is 
replaced with nonfunctional scar tissue. However, the problem 
of scar formation is perhaps greatest with respect to its role in 
devastating fibrotic diseases where scar tissue often times fatally 
overtakes normal tissue function.
Scars are essentially large deposits of extracellular matrix and 
collagen that are deposited by activated fibroblasts in response 
to tissue damage. After an injury, inflammatory mediators are 
immediately recruited and activated. Numerous cell types are 
involved in this response which includes the production and 
excretion of various growth factors and cytokines such as the 
well-studied TGF-β, IL-6, IL-8 and others.
Tissue injury involves disruption of capillaries and immediate-
ly triggers activation of platelets which begin a clotting cas-
cade. Inflammatory events follow with recruitment of neutro-
phils which secrete a variety of growth factors and cytokines. 
Monocytes arrive to facilitate changes in the wound matrix and 
macrophages release factors that activate fibroblasts to begin 
adding hyaluronate and glycoproteins such as fibronectin to the 
extracellular matrix (ECM). Gradually, these fibroblasts shift to 
producing proteoglycans and collagen which are then deposited 
at the wound site. Over the course of several days, macrophages 
and fibroblasts work to remodel the matrix and thus convert the 
granulation tissue into scar tissue (Harty, 2003). 
Studies comparing scarless fetal wounds to adult wounds have 
found significant differences in the levels of proinflammatory cy-
tokines such as IL-6 and IL-8. Liechty et al. (1998) grafted adult 
and fetal skin subcutaneously into SCID mice, wounded the site 
and subsequently excised the wound after varying lengths of time. 
The presence of IL-8 was confirmed using reverse transcription 
polymerase chain reaction (RT-PCR). Their results showed that 
fetal fibroblasts produced significantly less IL-8 at baseline (50 
+/- 6 pg/mL versus 450 +/- 115 pg/mL, P < 0.001). IL-8 mRNA 
was detected in unstimulated adult fibroblasts but not in fetal 
fibroblasts and much less IL-8 mRNA was detected in stimulated 
fetal fibroblasts than in adult fibroblasts. IL-8 mRNA was detect-
ed 4 hours after wounding in both fetal and adult wounds but by 
12 hours no IL-8 mRNA was detected in fetal wounds, whereas 
IL-8 mRNA persisted for up to 72 hours in adult wounds.
In a similar experiment, Liechty et al. (2000a) excised incisional 
wounds and examined them for IL-6 mRNA quantification by RT-
PCR. As with IL-8, fetal fibroblasts produced less IL-6 protein and 
mRNA at all points examined (P < 0.01 vs adult). IL-6 mRNA was 
detected 4 hours after wounding in both fetal and adult wounds. 
By 12 hours there was no IL-6 mRNA in the fetal wounds but the 
adult wounds had IL-6 mRNA persisting to 72 hours. In this ex-
periment, another set of grafts had 5 micrograms of IL-6 injected 
at wounding and the wound subsequently harvested at 7 days for 
analysis. The wounds with administered IL-6 resulted in scar for-
mation. Since these cytokines are responsible for the recruitment 
and activation of various leukocytes including macrophages, the 
diminished inflammatory response by fetal tissues may explain 
the lack of cellular recruitment and inflammation in fetal wound 
healing and further suggests that the inflammatory response 
plays a key role in the process of scar formation.
One well studied growth factor, TGF-β, exists as three known 
isoforms and is involved in many aspects of wound healing, from 
the immediate inflammatory response to matrix deposition 
(Adzick & Lorenz, 1994). In response to tissue injury, macro-
phages release TGF-β which stimulates the deposition of collagen 
and other matrix components by fibroblasts, thus implicating it in 
the etiology of fibrosis. Specifically, the TGF-β1 and TGF-β2 iso-
forms have been directly implicated in the fibrotic response and 
formation of scar tissue. Whitby and Ferguson (1991) detected 
both TGF-β1 and TGF-β2 isoforms with immunolocalization in 
adult wounds but not in fetal wounds. In a pioneer study, Shah et 
al. (1992) studied the effect of reduced levels of TGF-β in adult 
rodent wounds by using various neutralizing agents. The results 
of that experiment indicated inhibited fibrosis and scar forma-
tion. In another similar experiment, Shah et al. (1994) injected a 
polyclonal neutralizing antibody to TGF-β1, 2 into full-thickness 
cutaneous wounds of adult rodents just prior to wounding or 
within 24 hours of wounding and repeated daily for two days 
post-wounding. The effect was successful reduction in scarring. 
Numerous similar studies have been performed that confirm 
these results with more or less comparable data (Singer, et al. 
2009; Shah, et al. 2000). Conversely, up-regulation of these TGF-β 
isoforms via exogenous application resulted in excessive scar 
formation in a number of animal models (Lin, et al. 1995; Wang, 
et al. 1999; Lanning, et al. 1999). Thus direct evidence exists that 
increased levels of TGF-β1 and TGF-β2 play an important role in 
the fibrotic response and suggests that manipulation of TGF-β 
levels may provide an efficient strategy of reducing scar formation.
The culpability of TGF-β in the formation of scar tissue is fur-
ther supported by studies that have investigated the cellular and 
molecular differences abnormal scar formation such as keloid 
and hypertrophic scars. Experimental evidence suggests that 
upregulation of TGF-β is necessary for the excessive scarring 
characteristic of these pathologies (Lee, et al. 1999; Campaner, 
et al. 2006). Wang et al. (2000) compared the levels of TGF-β1 
mRNA in hypertrophic scar tissue and normal skin and found 
that hypertrophic scar tissues expressed five-fold more TGF-β1 
mRNA than normal skin per unit of wet weight. TGF-β1 mRNA 
expression in 5 pairs of fibroblast cultures derived from hyper-
trophic scar tissue also was found to be significantly elevated as 
compared to those derived from normal cells (116 +/- 6 vs. 97 
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+/- 7, p = 0.017). Additionally, Schmid (1998) demonstrated by 
immunohistochemistry and in situ hybridization, that hypertro-
phic scars exhibit unresolved persistent overexpression of TGF-β 
receptors by fibroblasts leading to overproduction of matrix pro-
tein and subsequent fibrosis. 
However, although the TGF-β1 and TGF-β2 isoforms have been 
implicated in scar formation, a third isoform has been shown to 
reduce scarring. Whitby and Ferguson (1991) demonstrated that 
fetal wounds express low levels of TGF-β1 and TGF-β2 but high 
levels of the third isoform, TGF-β3 (Table 1).
This implied that the ratio of TGF-β isoforms in wounded tissue 
may be the key to understanding the mechanism of wound heal-
ing and whether or not a scar forms. Shah et al. (1995) confirmed 
this hypothesis when they demonstrated that pan-neutralization 
of all three known TGF-β isoforms in linear incisions made on 
rats did not improve scarring, while exogenous application of 
TGF-β3 resulted in marked improvement in scarring and even 
scarless healing. Numerous studies have exploited this therapeu-
tic approach of increasing the relative ratio of TGF-β3 to TGF-β1 
and TGF-β2 with novel pharmaceutical agents (Ferguson, O’Kane, 
2004) (Figure 1).
The first clinical application of human recombinant TGF-β3, 
avotermin (Juvista; Renovo, UK) administered as an intradermal 
injection at the time of surgery, had shown promise in reduc-
ing scarring in controlled, double-blind, randomized phase I/
II clinical studies (Durani, et al. 2008). So et al. (2011) studied 
sixty patients (35 men and 25 women; age, 19 to 78 years; 53 
Caucasians; scar length, 5 to 21 cm) who received intradermal 
Table 1






Summary of relative TGF-β isoform differences in scarless fetal wound healing 
and scar-forming adult wound healing� (Ferguson, O’Kane, 2004)�
Figure 1
(a) Placebo-treated incisional rat wound compared with (b) scarless healing in TGF-β3-treated wound 84 days post-wounding (Ferguson, O’Kane, 2004)�
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histological score - 0.5
(a)
normal scar
histological score - 4
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avotermin (200 ng/100 μl/linear cm wound margin) and placebo 
to wounds immediately after scar revision surgery and again 24 
hours later. Primary efficacy was measured as a total scar score 
derived from a visual analogue scale and scored by a lay panel 
from standardized photographs from 1 to 7 months following 
treatment. Profilometry showed a greater reduction in scar sur-
face area from baseline with avotermin treatment compared with 
placebo and histologic analysis showed collagen organization that 
more closely resembled normal skin. However, an earlier study 
of dermal ulcers on the ears of female rabbits had demonstrat-
ed only that exogenous topical TGF-β3 had accelerated wound 
healing but with no improvement in scar morphology and prom-
inence. Wu et al. (1997) showed that the use of TGF-β3 (0.3-0.75 
microgram per wound) increased granulation tissue formation 
by more than 100% (P < .005) but no significant difference in the 
hypertrophic index was noted as compared with controls. In fact, 
phase III trials of avotermin failed to meet primary and secondary 
endpoints, suggesting that the difference between scarless and 
scar-forming wound healing is perhaps more complex than simply 
altering the ratio of TGF-β isoforms (Penn, et al. 2012) .
Interestingly, a number of studies have demonstrated that even 
in fetal wounds, exogenously applied TGF-β can induce fibrosis. 
McCallion and Ferguson (1996) applied exogenous TGF-β1 to 
fetal wounds and observed a profound fibrotic response with 
scar formation. Krummel et al. (1988) showed that the addition 
of TGF-β to polyvinyl alcohol sponges implanted in fetal rabbits 
produced fibrosis. Sullivan et al. (1995) also examined human scar-
less fetal wounds transplanted subcutaneously into adult nude 
mice. Immunohistochemistry performed on the wounds did not 
show TGF-β staining. In a second part of the study, a slow-release 
disk with varying amounts of TGF-β1 was placed beneath the 
fetal skin graft at the time of wounding. Marked scarring in these 
fetal grafts was observed fourteen days post-wounding with the 
size of the scar proportional to the amount of TGF-β1 applied. 
These data suggest that the cellular mechanism of scar formation 
characteristic of adult wound healing is present in fetal wounds. 
The absence of scar formation in fetal wounds thus implies active 
suppression of these inflammatory mediators that have been im-
plicated in scar formation.
The concept of immune inflammatory suppression as the mech-
anism of scarless healing has been investigated further by testing 
with the known anti-inflammatory cytokine IL-10. IL-10 deacti-
vates macrophages and inhibits expression of both IL-6 and IL-8. 
Liechty et al. (2000b) hypothesized that the diminished levels of 
IL-6 and IL-8 they had revealed in a previous study were in fact 
due to the effects of IL-10. They developed a new syngeneic mu-
rine model of fetal wound repair in which 15-day-gestation skin 
from either normal or transgenic IL-10 knockout mice was graft-
ed to the back of the same strain adult mice. Incisions were made 
in the grafts after 5 days, which were then harvested at 1 week 
and analyzed for inflammatory response and scar formation. The 
normal fetal skin grafts showed minimal inflammation and were 
histologically consistent with scarless healing. The IL-10 knockout 
fetal skin grafts, in contrast, displayed significant inflammation and 
scar formation. Thus, the anti-inflammatory effects of IL-10 are 
necessary for active suppression of the inflammatory response 
leading to the observed paucity of macrophages, less TGF-β re-
lease, and consequently, less scarring.
The impact of IL-10-induced immune suppression is a key fac-
tor in scarless wound healing. Yamamoto et al. (2001) performed 
Northern blot analysis to show that IL-10 differentially regulates 
collagen deposition by downregulation of TGF-β1-induced col-
lagen mRNA. In a phase II randomized controlled clinical trial, 
Kieran et al. (2013) demonstrated that exogenous IL-10 applied 
to human incisional wounds reduced scarring and generally im-
proved scar appearance.
In a recent study, Wise et al. (2014) studied the effects of a pu-
rified IL-10 homolog derived from orf virus (ovIL-10). Orf virus 
infections induce persistent skin lesions that are reminiscent of 
sustained wound healing, yet surprisingly resolve with minimal 
scarring (Gurel 2002), and genetic studies have discovered that 
orf virus encodes for a variety of factors that allow it to subvert 
host immune responses, including an IL-10 homolog (Fleming 
2007). Wise et al. made excisional wounds in mice and divided 
them into four groups. The first three groups were treated with 
either recombinant murine IL-10 (mIL-10) or ovIL-10 in a buff-
ered saline solution (PBS), or PBS alone, while the fourth group 
received no treatment. The wounds were biopsied at varying 
times and analyzed. Histological analysis revealed that wounds 
treated with ovIL-10 exhibited accelerated healing as evident 
by increased wound reepithelialization as compared to controls. 
Reduction in visible scarring was also evident and quantitative 
PCR confirmed decreased levels of key proinflammtory medi-
ators. Thus supporting evidence exists that limiting the inflam-
matory response in wound healing can improve the quality of 
wound repair.
TGF-β is an upstream regulator of the cyclooxygenase (COX) 
pathway (Wilgus, et al. 2004). COX enzymes catalyze the con-
version of membrane phospholipid-derived arachidonic acid into 
prostaglandins which are known mediators of the inflammatory 
response. Western blot analysis and immunohistochemistry of 
biopsied hypertrophic and keloid scar lesions revealed significant 
overexpression of COX-1 and COX-2 isoforms, respectively, in 
comparison to normal dermal tissue which further suggests a sig-
nificant role these enzymes play in the pathogenesis of these ab-
normal scarring processes (Rossiello, et al. 2009). Indeed, TGF-β 
was shown to induce prostaglandin production in cultured 
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fibroblasts via COX-1 overexpression (Diaz, et al. 1998).
The significance of COXs in the etiology of pathological scarring 
such as keloids and hypertrophic scars has led to the investiga-
tion of its role in wound healing in general. Wilgus et al. (2003) 
examined the role of COX inhibitors in reducing scar formation. 
Celecoxib belongs to the family of nonsteroidal anti-inflammato-
ry drugs (NSAIDs) which target the COX enzymes. Specifically, 
celecoxib selectively targets COX-2 and prevents its enzymatic 
activity and subsequent production of prostaglandins including 
prostaglandin E2 (PGE2). Wilgus et al. made full-thickness inci-
sions in mice and closed the wounds with stainless steel wound 
clips to mimic surgical wounds. The staples were removed after 
5 days. The wounds were treated topically immediately after 
wounding and for up to 14 days daily with either 200 µl of the 
vehicle control (K-Y Jelly; Ortho Pharmaceutical Corp., Raritan, 
NJ) or with 1 mg of celecoxib capsules (Celebrex®, Searle, St. 
Louis, MO) dissolved in 200 μl of vehicle such that 200 μl con-
tained 1 mg of the drug. 
Skin sections were excised and analyzed. Immunohistochemical 
analysis using an antibody specific for the neutrophil surface 
marker Ly-6G, revealed a stark contrast between vehicle-treated 
and celcoxib-treated wounds. While a major inflammatory re-
sponse, manifested as a massive infiltration of neutrophils, was 
observed in the vehicle-treated wounds in comparison to un-
wounded tissue, wounds treated with celecoxib were virtually 
devoid of neutrophils.
Additionally, Biotrak enzyme immunoassays (EIA; Amersham-
Pharmacia, Piscataway, NJ) were used to quantify the concentra-
tion of PGE2. An approximately 50% decrease in wound PGE2 
levels was observed in wounds treated with celecoxib (p < 0.05). 
Levels of TGF-β1 were examined by Western blot analysis which 
revealed significantly lower levels in celecoxib-treated wounds 
compared to vehicle-treated wounds. These data were substanti-
ated by the observation of reduced scarring later on.
Wilgus et al. (2003) also reported that PGE2 promotes fibroblast 
proliferation and collagen synthesis consistent with known find-
ings (Lupulescu 1975) as well as their data showing decreased 
scar tissue deposition in treatment with celecoxib. This seems to 
be corroborated by the fact that lower levels of the proinflam-
matory fibrogenic TGF-β1 were detected. A similar result was 
presented by Miyajima et al. (2001) who also showed the ability 
of COX-2 inhibitors to reduce TGF-β levels and thus fibrosis.
The demonstrated effect of treatment with topical celecoxib in 
reducing scar formation in adult wound healing led Wilgus et al. 
(2004) to examine the role of COX-2 in scarless fetal wound 
repair. Incisions were made in the dorsum of fetal mice at either 
15 (E15) or 18 (E18) days after the detection of a vaginal plug 
using microsurgical scissors. These time points represent the ages 
at which either scarless or fibrotic healing occurs. Normal E15 
and E18 skin were harvested as controls along with the wounded 
samples at varying times for examination. Immunohistochemical 
staining at 24 hours post-wounding demonstrated COX-2 pro-
tein expression only in wounded E18 skin but not in E15 skin. 
Western blot was also used to detect COX-2 protein and the 
levels were analyzed by image analysis software. Levels of COX-2 
protein as well as PGE2 were higher in wounds introduced at E18 
compared to those at E15, implying that COX-2 is involved in the 
process of scar tissue formation.
It is thought that one mechanism by which PGE2 contributes to 
scar deposition is by increasing the rate of fibroblast prolifera-
tion. Indeed, Wilgus et al. showed that exogenous PGE2 applied 
to fetal fibroblast cultures resulted in statistically significant (p 
< 0.05 compared to untreated cells) dose dependent increased 
proliferation.
However, conflicting data suggest that fibroblasts from other or-
gans do not respond in the same way to increased PGE2 levels. 
For example, PGE2 reduces proliferation and collagen synthe-
sis by lung fibroblasts. This suggests that PGE2 can have varied 
effects perhaps resulting from differences in the expression or 
activity of various PGE2 receptors (Wilgus 2004).
Thus, the mechanism of PGE2-induced scarring could involve a 
number of plausible options. PGE2 could be contributing to the 
inflammatory response which has already been implicated in scar 
formation. Alternatively, PGE2 could be promoting scar depo-
sition through increases in the profibrotic TGF-β. Lastly, PGE2 
could be directly encouraging scar formation by stimulating fi-
broblast proliferation. 
Of note, however, is that although keloid and hypertrophic scars 
were found to express high levels of COX proteins, Yeh et al. 
(2006) found that fibroblasts derived from keloid patients exhib-
ited diminished capacity to produce PGE2, in line with the studies 
that identified PGE2 as an antifibrotic agent. In this experiment, 
fibroblast cultures were stimulated using the proinflammatory 
cytokine IL-1 which is known to activate fibroblasts and induce 
the formation/release of COX pathway products such as PGE2 
(Elias, et al. 1987). The effects of PGE2 on the synthesis of colla-
gen were determined using enzyme-linked immunosorbant assay 
(ELISA) kits. According to these data, the excessive deposition of 
collagen characteristic of keloids may in fact be due to decreased 
levels of PGE2 rather than increased.
The conflicting and perhaps confounding data surrounding PGE2 
and its effect on fibroblast proliferation and collagen synthesis 
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necessitate further investigation into the exact mechanisms by 
which this enzyme affects the healing process. Such contradictory 
data does not now lend to sufficient understanding that can lead 
to exploitation and development of therapeutic clinical applica-
tions in the treatment or prevention of scarring. In fact, some 
have suggested that the use of NSAIDs and COX-2 inhibitors 
may even exacerbate wound scarring because of their ability to 
decrease PGE2 production (Su, et al. 2010).
Until such time as the role of PGE2 and its effect on wound 
healing becomes better understood, a more promising approach 
to treatment and/or prevention of scarring would seem to be 
manipulation of the various TGF-β isoforms, which perhaps play a 
more direct role in the process of scar formation .
Already, clinical trials that manipulated the ratio of TGF-β iso-
forms have proven efficacy in the controlling scarring, although 
not without some failure. Further investigation into the exact 
role the various isoforms of TGF-β play in the process of wound 
healing can hopefully lead to the development of better targeted 
therapies to reduce scarring and perhaps even cure the numer-
ous fibrotic diseases. 
Conclusion
In this review, the underlying mechanisms of scar formation in 
wound healing were explored. The various TGF-β isoforms (and 
their ratio) seem to play a vital role by regulating the inflammato-
ry response although the process is undoubtedly more complex. 
The role of COX and PGE2 remains unclear with contradictory 
evidence pointing either to a reduction in scarring or perhaps 
exacerbation of the problem. The focus of potential therapeutic 
agents should for now remain dedicated to TGF-β as past studies 
have already proven potential in reducing scarring, while the other 
options reviewed here remain clouded in uncertainty. Research 
has further investigated the effects of interactions between cell 
adhesion molecules such as integrins and cadherins and the vari-
ous TGF-β isoforms in an effort to explore targeted therapeutic 
agents (Eslami, et al. 2009; Agarwal, 2014). Additionally, research 
has explored TGF-β as a potential target for anti-scarring gene 
therapy (Liu, et al. 2004). These and other efforts show promise in 
the development of successful clinical means of controlling scar-
ring and perhaps even fibrotic disease.
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